Literature DB >> 27428935

Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH.

C Kearon1, W Ageno2, S C Cannegieter3, B Cosmi4, G-J Geersing5, P A Kyrle6.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27428935     DOI： 10.1111/jth.13336

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  75 in total

Review 1.  Who should get long-term anticoagulant therapy for venous thromboembolism and with what?

Authors:  Marc Alan Rodger; Gregoire Le Gal
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism.

Authors:  Craig I Coleman; Alexander G G Turpie; Thomas J Bunz; Jan Beyer-Westendorf
Journal:  J Thromb Thrombolysis       Date:  2018-10       Impact factor: 2.300

Review 3.  The 2016 American College of Chest Physicians treatment guidelines for venous thromboembolism: a review and critical appraisal.

Authors:  James Demetrios Douketis
Journal:  Intern Emerg Med       Date:  2016-10-20       Impact factor: 3.397

4.  Stopping anticoagulation in a woman with unprovoked venous thromboembolism.

Authors:  Faizan Khan; Grégoire Le Gal; Marc A Rodger
Journal:  CMAJ       Date:  2017-09-05       Impact factor: 8.262

Review 5.  Who should get long-term anticoagulant therapy for venous thromboembolism and with what?

Authors:  Marc Alan Rodger; Gregoire Le Gal
Journal:  Blood Adv       Date:  2018-11-13

6.  Incidence of residual perfusion defects by lung scintigraphy in patients treated with rivaroxaban compared with warfarin for acute pulmonary embolism.

Authors:  Ming Sheng Lim; Dee Nandurkar; Ian Jong; Anita Cummins; Huyen Tran; Sanjeev Chunilal
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

7.  Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism.

Authors:  Clive Kearon; Sameer Parpia; Frederick A Spencer; Trevor Baglin; Scott M Stevens; Kenneth A Bauer; Steven R Lentz; Craig M Kessler; James D Douketis; Stephan Moll; Scott Kaatz; Sam Schulman; Jean M Connors; Jeffrey S Ginsberg; Luciana Spadafora; Vinai Bhagirath; Patricia C Liaw; Jeffrey I Weitz; Jim A Julian
Journal:  Blood       Date:  2018-02-28       Impact factor: 22.113

Review 8.  Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?

Authors:  Fionnuala Ní Áinle; Barry Kevane
Journal:  Blood Adv       Date:  2020-11-10

9.  Risk of recurrent venous thromboembolism according to baseline risk factor profiles.

Authors:  Martin H Prins; Anthonie W A Lensing; Paolo Prandoni; Philip S Wells; Peter Verhamme; Jan Beyer-Westendorf; Rupert Bauersachs; Henri Bounameaux; Timothy A Brighton; Alexander T Cohen; Bruce L Davidson; Hervé Decousus; Ajay K Kakkar; Bonno van Bellen; Akos F Pap; Martin Homering; Miriam Tamm; Jeffrey I Weitz
Journal:  Blood Adv       Date:  2018-04-10

10.  Clinical relevance of chronic respiratory disease in Korean patients with pulmonary thromboembolism.

Authors:  Hyeyoung Park; Seung-Ick Cha; Jae-Kwang Lim; Kyung-Min Shin; Yong-Hoon Lee; Hyewon Seo; Seung-Soo Yoo; Shin-Yup Lee; Jaehee Lee; Chang-Ho Kim; Jae-Yong Park
Journal:  J Thorac Dis       Date:  2019-06       Impact factor: 2.895
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.